Hence, the enrolled patients were all likely to be characterized by a high pre-ADAMTS13 testing probability of TTP, that perhaps explains the disproportion between the two patient groups (80% of patients had severe ADAMTS13 deficiency). This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.